IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Apotex Pty Ltd v Warner Chilcott Company, LLC [2016] APO 29
Patent Application: 2011218625
Title:Dosage forms of risedronate
Patent Applicant: Warner Chilcott Company, LLC
Opponent: Apotex Pty Ltd
Delegate: K. Wagg
Decision Date: 23 May 2016
Hearing Date: 1 March 2016
Catchwords: PATENTS – Opposition unsuccessful–claims are novel and inventive because the cited prior art teaches away from the opposed claims–Costs awarded against the opponent.
Representation: Patent Applicant: Ben Fitzpatrick of Counsel instructed by David Miles and Bernard Nutt of Pizzeys
Opponent:Craig Smith of Counsel instructed by James Cherry and Sarah Hennebry of Freehills
IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Patent Application: 2011218625
Title:Dosage forms of risedronate
Patent Applicant: Warner Chilcott Company, LLC
Date of Decision: 23 May 2016
DECISION
The opposition fails.
Subject to appeal, patent applicant number 2011218625 is to proceed to grant.
I award costs according to Schedule 8 against Apotex Pty Ltd.
REASONS FOR DECISION
Patent application number 2011218625 (the opposed application) was filed on 29 August 2011. It is a divisional of application number 2005330654 (the parent application), now withdrawn. The Applicant is Warner Chilcott Company, LLC (the Applicant). The application was examined by the Commissioner and acceptance was advertised on 20 March 2014. On 20 June 2014, Apotex Pty Ltd (the Opponent) filed a Notice of Opposition.
A hearing was held on 1 March 2016 in Canberra to decide the opposition. The Applicant was represented by Ben Fitzpatrick of Counsel instructed by David Miles and Bernard Nutt of Pizzeys. The Opponent was represented by Craig Smith of Counsel instructed by James Cherry and Sarah Hennebry of Freehills.
The request for examination was filed prior to 15 April 2013. As a consequence, substantive amendments of the Patents Act 1990 brought about by the Intellectual Property Laws Amendment (Raising the Bar) Act 2012 do not apply to the present patent application. This includes the amendment to subsection 60 (3A) that allows the Commissioner to refuse a patent application if satisfied on the balance of probabilities that a ground of opposition exists. I also note that any subsequent reference to the Patents Act relates to the Patents Act1990 (the Act), prior to amendment by the Intellectual Property Laws Amendment (Raising the Bar) Act 2012.
Standard of proof
The onus of proof in this opposition proceeding rests with the Opponent, who must demonstrate that it is clear that a valid patent cannot be granted (F.Hoffman-La Roche AG v New England Biolabs Inc [2000] FCA 283 at [67]; 50 IPR 305; Commissioner of Patents v Sherman [2008] FCAFC 182 at [18]; 79 IPR 426).
The opposition
The Statement of Grounds and Particulars identified seven grounds of opposition. At the hearing, the opposition was limited to the grounds of novelty and inventive step.
The parties relied upon evidence by several declarants. Evidence in support is as follows:
Evidence in Support Date of declaration Declarant Annexes Abbreviation 23 October 2014 Robert William Milne
Keep reading for free
Create a free CaseChat account to read Apotex Pty Ltd v Warner Chilcott Company, LLC and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2016] APO 29
- Decision Date
CaseChat Overview and Summary
Background
Background to the litigation
The matter came before the Australian Patent Office as an opposition to the patent application filed by Apotex Pty Ltd on 20 June 2014. The opposition was limited to the grounds of novelty and inventive step. A hearing was held on 1 March 2016 in Canberra. Warner Chilcott Company, LLC, the patent applicant, was represented by Ben Fitzpatrick of Counsel, and Apotex Pty Ltd, the opponent, was represented by Craig Smith of Counsel. The decision, rendered on 23 May 2016, dismissed the opposition, allowing the patent application to proceed to grant, and awarded costs against Apotex Pty Ltd.
Decision
Reasons for decision
1. Does the prior art document BR 0106601-3 A (LIBBS PHARMACEUTICAL COMPANY LTDA.) anticipate the claims of the opposed application?
2. Does the combination of the prior art document BR 0106601-3 A and common general knowledge render the claims of the opposed application obvious?
Held
1. The opposition against patent application number 2011218625 is unsuccessful on both grounds of novelty and inventive step.
2. Subject to appeal, patent applicant number 2011218625 is to proceed to grant.
3. Costs are awarded according to Schedule 8 against Apotex Pty Ltd.
Ratio Decidendi
Legal Principle Established
The Delegate of the Commissioner of Patents, K. Wagg, considered the grounds of opposition regarding the novelty and inventive step of the opposed application. In terms of novelty, the Delegate found that BR 0106601-3 A (LIBBS PHARMACEUTICAL COMPANY LTDA.) did not anticipate the claims of the opposed application because it did not provide clear and unmistakable directions for the specific dosages of risedronate required by the claims. Although BR '601 disclosed the use of risedronate, it did not specify the dosages of risedronate that are essential to the invention as claimed in the opposed application.
Regarding the inventive step, the Delegate determined that the combination of BR '601 and common general knowledge would not have led the person skilled in the art to the opposed application as a matter of routine. The document BR '601 taught using lower quantities of bisphosphonate compared to the standard doses available at the priority date, and the evidence did not demonstrate that it would be routine to disregard this teaching and use the standard doses.
The Delegate concluded that the opposition was unsuccessful on both grounds of novelty and inventive step, and therefore, the patent application number 2011218625 is to proceed to grant, subject to appeal. Costs were awarded to the patent applicant, Warner Chilcott Company, LLC, against the opponent, Apotex Pty Ltd.